JANSSEN PHARMACEUTICAL K.K.

🇯🇵Japan
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Phase 1
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Daratumumab
First Posted Date
2014-04-17
Last Posted Date
2016-09-26
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
9
Registration Number
NCT02116569

A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 in Japanese Healthy Participants

Phase 1
Withdrawn
Conditions
Healthy
Interventions
Drug: CR8020
Drug: Placebo
First Posted Date
2013-12-19
Last Posted Date
2019-03-25
Lead Sponsor
Janssen Pharmaceutical K.K.
Registration Number
NCT02015533

A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 in Japanese Healthy Participants

Phase 1
Withdrawn
Conditions
Healthy
Interventions
Drug: Placebo
Drug: CR6261
First Posted Date
2013-12-19
Last Posted Date
2017-02-06
Lead Sponsor
Janssen Pharmaceutical K.K.
Registration Number
NCT02016066

A Study to Evaluate the Safety and Efficacy of Ultiva (Remifentanil Hydrochloride) in Pediatric Participants General Anesthetised

Phase 3
Completed
Conditions
Anesthesia
Interventions
Drug: Remifentanil
First Posted Date
2013-11-28
Last Posted Date
2015-11-16
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
80
Registration Number
NCT01998165

A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis

First Posted Date
2013-09-18
Last Posted Date
2016-03-09
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
79
Registration Number
NCT01945086

A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia

Phase 1
Completed
Conditions
Schizophrenia
Interventions
Drug: Paliperidone palmitate
First Posted Date
2013-09-16
Last Posted Date
2013-09-16
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
76
Registration Number
NCT01942382

A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.

Phase 3
Completed
Conditions
Colitis, Ulcerative
Interventions
Other: Placebo
Drug: Golimumab
First Posted Date
2013-05-29
Last Posted Date
2017-04-05
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
144
Registration Number
NCT01863771

A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis

Phase 2
Completed
Conditions
Palmoplantaris Pustulosis
Interventions
Drug: CNTO 1959
Drug: Placebo
First Posted Date
2013-05-03
Last Posted Date
2015-11-20
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
49
Registration Number
NCT01845987

A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese Participants

Phase 4
Completed
Conditions
Healthy
Interventions
Drug: Darunavir
Drug: Ritonavir
First Posted Date
2013-03-14
Last Posted Date
2013-04-10
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
8
Registration Number
NCT01810887

A Single-Dose Pharmacokinetics and Safety Study of TMC278 in Healthy Adult Japanese Participants

Phase 4
Completed
Conditions
Healthy
Interventions
Drug: TMC278
First Posted Date
2013-03-05
Last Posted Date
2014-03-19
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
8
Registration Number
NCT01804244
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy